Abiopharma

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

uniQure to Announce Third Quarter 2025 Financial Results

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

NeoGenomics to Participate in Upcoming Investor Conferences

Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update